NIDDK
|
NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) |
RFA-DK-26-006 |
2024-12-18 |
2025-07-19 |
The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. |
NIDDK
|
High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) |
PAR-25-277 |
2024-12-11 |
2027-10-16 |
The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this NOFO is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. |
NIDDK
|
NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional) |
RFA-DK-26-001 |
2024-12-09 |
2025-06-11 |
This Notice of Funding Opportunity (NOFO) invites applications that propose a Center for Diabetes Translation Research (CDTR) to support research across the translational science spectrum (i.e., bedside to clinical practice and community settings, dissemination and implementation research). |
NIDDK
|
Request for Information (RFI): Research Strategies for Addressing Obesity Heterogeneity |
NOT-DK-24-026 |
2024-09-24 |
2024-11-29 |
This Request for Information (RFI) invites input on research strategies to address obesity heterogeneity. It is intended to solicit input from a broad array of interested individuals, groups and communities including the biomedical and behavioral research community, physicians and other health care professionals, industry, and other interested parties including public health or social service officials at the federal, state, county and community levels, community organizations, those in educational settings, payers, media, advocacy groups and the general public. |